The only approved imaging agent that specifically targets prostate cancer.
ProstaScint is the only commercially available diagnostic imaging agent approved by the FDA that specifically targets prostate cancer cells that have spread to tissue outside of the prostate gland. It consists of a novel murine monoclonal antibody that, when conjugated to a linker-chelator and radiolabeled, binds distinctly to Prostate Specific Membrane Antigen (PSMA). PSMA is a glycoprotein expressed by prostate epithelium, which is up regulated in prostate cancer. PSMA is expressed on metastatic prostate cancer tissue. Combined with a CT or MRI scan, this fusion imaging study helps to determine the location and extent of metastatic lymph node disease. Knowing whether the prostate cancer is confined to the gland or has spread to the lymph nodes helps physicians determine appropriate patient management.
- The only imaging agent that specifically targets prostate cancer cells
- Approved by the US FDA in both newly diagnosed, high risk patients, and patients suspected of having recurrent disease
- American Cancer Society specifically recognizes ProstaScint in current prostate cancer diagnosis guidelines